Cantor Fitzgerald reiterates Anteris Technologies stock rating on commercial progress

Investing.com reports that Cantor Fitzgerald has reaffirmed its Overweight rating and set a $15.00 price target on Anteris Technologies Global (NASDAQ: AVR) stock. The company's shares have increased by 59% over the past year, currently trading at $6.18. However, the firm believes the stock may be overvalued compared to its estimated Fair Value.

Cantor Fitzgerald highlights Anteris' progress in commercial readiness, noting that the company's third quarter of 2026 saw a pivotal shift. Additionally, the PARADIGM trial is expanding market access. In October, Germany granted clearance, complementing existing U.S. approval and strengthening Anteris' European presence. The firm anticipates trial enrollment completion in the first quarter of 2027.

Recently, TCT data has extended DurAVR's performance results to a second valve size, a development previously flagged by Cantor Fitzgerald. The company has not utilized its $250 million at-the-market offering facility, indicating strong financial health. Cantor Fitzgerald emphasizes that Anteris remains well-capitalized to achieve its commercial objectives, with a robust current ratio of 12.45, suggesting more cash than debt on its balance sheet.

The rating reaffirmation comes after a fireside chat with Anteris' Chief Medical Officer, Dr. Chris Meduri, who discussed the clinical case for DurAVR and the trial design behind the PARADIGM trial. This conversation also emphasized the device's unique aspects from a physician's perspective. Cantor Fitzgerald's reaffirmed Overweight rating underscores its continued confidence in Anteris' potential, providing investors with valuable insights into the company's progress.